Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 995 across all filing types
Latest filing 2020-01-22 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging 1
Regulatory Filings Classification · 95% confidence The document is a company announcement from Telix Pharmaceuticals Limited about the FDA granting approval for a clinical study (ZIRCON Renal Cancer Imaging Study). It discusses regulatory approval, study recruitment, and operational details related to a clinical trial. There are no financial statements, earnings data, or detailed financial analysis. The document is relatively short (3329 characters) and serves as a news release or regulatory update rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is not a report publication announcement since it does not mention the release or availability of a report. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA approval and study commencement, which does not fit other more specific categories.
2020-01-22 English
Appendix 3G - issue of unlisted share options 14 pages 369.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G notification filed by Telix Pharmaceuticals Limited, detailing the issue and lapse of unlisted share options. It includes specific information about the number of options issued, exercise prices, expiry dates, and recipients, including key management personnel. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding equity securities issued under an employee incentive scheme. It is not a financial report, earnings release, or management discussion, but a regulatory announcement about share option issuance and lapses. This fits the category of Share Issue/Capital Change (SHA), as it concerns the issuance and lapse of share options, which are capital changes.
2020-01-15 English
NDA Clinical Briefing Package Submitted to the US FDA 2 pages 189.3KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Telix Pharmaceuticals Limited about submitting a clinical briefing package to the US FDA for a New Drug Application (NDA) for their product TLX591-CDx. It discusses the submission process, the product details, and expected future updates. The document is relatively short (3391 characters) and does not contain any financial data, financial statements, or detailed regulatory filings. It is clearly an announcement about a regulatory submission related to a drug approval process, not a financial report, earnings release, or management discussion. It also does not fit into categories like M&A, board changes, or voting results. Given the nature of the content and length, it best fits the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-12-26 English
Zircon P3 IND submitted to US FDA 2 pages 190.2KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the submission of a Phase 3 Investigational New Drug (IND) application to the US FDA by Telix Pharmaceuticals Limited. It discusses clinical trial plans, drug development, and regulatory submission status. There are no financial statements, earnings data, or detailed financial analysis. The document is an update on a capital/financing or clinical development activity rather than a financial report or regulatory filing. It is not an Annual Report, Interim Report, Earnings Release, or any other financial filing. The content fits best under Capital/Financing Update (CAP) as it relates to a significant development in the company's drug pipeline and regulatory progress, which impacts the company's capital and financing outlook.
2019-12-23 English
TLX101 for Brain Cancer IPAX-1 Study Update 15 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a detailed clinical study presentation focusing on the progress, design, and results of a Phase I/II clinical trial (IPAX-1) for a drug candidate TLX101 targeting glioblastoma multiforme (GBM). It includes study objectives, patient recruitment status, safety and efficacy data, imaging results, manufacturing footprint, and future plans. There are no financial statements, regulatory certifications, voting results, or executive changes. The content is scientific and clinical trial progress oriented, typical of an Investor Presentation (IP) aimed at informing investors about the drug development pipeline, clinical progress, and commercial potential. The document length is substantial (12,688 characters), and it contains detailed data and visuals, consistent with an investor presentation rather than a brief announcement or regulatory filing. Therefore, the most appropriate classification is Investor Presentation (IP).
2019-12-22 English
Telix and Vic Cancer Centre receive Cancer Australia grant 2 pages 193.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals and collaborators have received a Cancer Australia research grant for a specific cancer research project. It discusses the grant details, the research focus, and background information about the company and the disease. There are no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no mention of any report publication or certification. The content is primarily an announcement of a research grant award, which is a general corporate announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other financial or regulatory filing. The closest fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2019-12-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.